| MSC exosome works through a protein-based mechanism of action |
34 |
| Carcinogens and DNA damage |
29 |
| LRRK2 links genetic and sporadic Parkinson's disease |
27 |
| Vitamin C and immune cell function in inflammation and cancer |
27 |
| Latest developments in MUC1 immunotherapy |
24 |
| Mucins: the frontline defence of the lung |
24 |
| Learning the ABCs one at a time: structure and mechanism of ABC transporters |
22 |
| Structure and function of the cytochrome P450 peroxygenase enzymes |
20 |
| Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments |
19 |
| Mammalian DNA methyltransferases: new discoveries and open questions |
19 |
| Towards a therapy for mitochondrial disease: an update |
18 |
| Molecular mechanisms involved in plant photoprotection |
18 |
| MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target |
17 |
| Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention |
16 |
| Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically? |
16 |
| Lysosomal membrane permeabilization as a cell death mechanism in cancer cells |
15 |
| Oxysterol research: a brief review |
15 |
| LRRK2 regulation of immune-pathways and inflammatory disease |
15 |
| Keeping the balance in NAD metabolism |
15 |
| The role of metal ions in the virulence and viability of bacterial pathogens |
14 |
| Coenzyme A, protein CoAlation and redox regulation in mammalian cells |
14 |
| Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting |
14 |
| Recent insights into lytic polysaccharide monooxygenases (LPMOs) |
14 |
| Signaling through plant lectins: modulation of plant immunity and beyond |
13 |
| Protein engineering: the potential of remote mutations |
13 |
| RHO GTPases in cancer: known facts, open questions, and therapeutic challenges |
13 |
| The role of the interleukin (IL)-6/IL-6 receptor axis in cancer |
13 |
| Membrane protein nanoparticles: the shape of things to come |
13 |
| RAS variant signalling |
13 |
| The 10-nm chromatin fiber and its relationship to interphase chromosome organization |
12 |
| Structure of the plant photosystem I |
12 |
| Structural dynamics of P-type ATPase ion pumps |
11 |
| Endothelial-to-haematopoietic transition: an update on the process of making blood |
11 |
| Phase-variable bacterial loci: how bacteria gamble to maximise fitness in changing environments |
11 |
| Storing memories: the distinct phases of Polycomb-mediated silencing of Arabidopsis FLC |
11 |
| O-linked mucin-type glycosylation in breast cancer |
11 |
| History and future of shotgun glycomics |
10 |
| Specialized ribosomes and the control of translation |
10 |
| The molecular mechanism of DHHC protein acyltransferases |
10 |
| Fantastic nuclear envelope herniations and where to find them |
10 |
| Emerging mechanisms of dynein transport in the cytoplasm versus the cilium |
10 |
| Answers to naysayers regarding microbial extracellular vesicles |
10 |
| PARPs in genome stability and signal transduction: implications for cancer therapy |
10 |
| Cryo-EM in drug discovery |
10 |
| MT1-MMP-dependent cell migration: proteolytic and non-proteolytic mechanisms |
10 |
| The mechanistic target of rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders |
10 |
| How is the acyl chain composition of phosphoinositides created and does it matter? |
10 |
| Membrane trafficking in osteoclasts and implications for osteoporosis |
10 |
| Nesprin-1/2: roles in nuclear envelope organisation, myogenesis and muscle disease |
9 |
| Review and perspective on mathematical modeling of microbial ecosystems |
9 |
